零星双边RCC的现实世界预后:基于倾向评分的同步和超时病例的比较
Jianyong Liu1, Shicong Lai2, Haoran Wang3,4
1Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
International journal of surgery (London, England)
|October 28, 2025
概括
同步双边细胞癌 (BRCC) 与甲时性BRCC相比,与更差的生存结果有关. 这项研究突出了BRCC患者管理的关键预后差异.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 双边细胞癌 (BRCC) 提出了独特的临床挑战.
- 了解同步和超时BRCC之间的预后差异对于患者管理至关重要.
研究的目的:
- 为了比较预后结果,特别是癌症特异性存活率 (CSS) 和整体存活率 (OS),同步和超时性零星双边细胞癌 (BRCC) 之间.
主要方法:
- 一项队列研究利用了监测,流行病学和最终结果 (SEER) 数据库 (2004-2021).
- 患者被分为同步性 (在6个月内诊断的瘤) 和超时性 (在6个月内诊断的瘤) 组.
- 使用倾向分数匹配 (PSM) 和考克斯回归分析来评估生存差异.
主要成果:
- 该研究包括4,694名BRCC患者;2,710名同步和1,984名超时.
- 在PSM之后,同步BRCC显示显著较差的CSS (HR=2.661) 和OS (HR=2.481) 与metachronous BRCC相比.
- 分层考克斯回归证实同步BRCC的CSS (HR=3.170) 和OS (HR=2.631) 较差.
结论:
- 同步散发性BRCC与超时性BRCC相比,与较低的存活率有关.
- 这些发现为BRCC患者的临床管理提供了宝贵的预后见解.
相关概念视频
01:21Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
01:20Comparing the Survival Analysis of Two or More Groups
548
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
548
01:24Kaplan-Meier Approach
556
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
556
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K